Brain immunology and immunotherapy in brain tumours.
Journal Article (Journal Article;Review)
Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet, seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of the immune system within the central nervous system (CNS) and altered the paradigm for successful immunotherapy. The impact of standard therapies on the response to immunotherapy is now better understood, as well. This new knowledge has implications for a broad range of tumours that develop within the CNS. Nevertheless, the requirements for successful therapy remain effective delivery and target specificity, while the dramatic heterogeneity of malignant gliomas at the genetic and immunological levels remains a profound challenge.
Full Text
Duke Authors
Cited Authors
- Sampson, JH; Gunn, MD; Fecci, PE; Ashley, DM
Published Date
- January 2020
Published In
Volume / Issue
- 20 / 1
Start / End Page
- 12 - 25
PubMed ID
- 31806885
Pubmed Central ID
- PMC7327710
Electronic International Standard Serial Number (EISSN)
- 1474-1768
Digital Object Identifier (DOI)
- 10.1038/s41568-019-0224-7
Language
- eng
Conference Location
- England